Pharmacology of Combined Treatment of Saxagliptin Hydrochloride and Glibenclamide Therapy to Treat Type-2 Diabetes

This review article presents the pharmacology of combined treatment of Saxagliptin hydrochloride and Glibenclamide therapy especially in type-2 diabetes. Saxagliptin hydrochloride is anti diabetic agent (dipeptidyl peptidase-4 inhibitor). Glibenclamide is also an anti-diabetic agent. If Glibenclamide is administered as a long term treatment and also in large quantities, the condition of patient becomes worse by causing sulphonylurea failure. And also occurrence of adverse effect of weight gain and hypoglycemia. The availability of newer agents such as dipeptidyl peptidase-4 inhibitors may allow for additional therapeutic combinations to improve glycaemic control without increasing the risk of adverse effects. Combination therapy of a DPP-4 inhibitor with a sub maximal dose of a sulphonylurea represents an alternative treatment approach that may provide improved glycaemic control earlier in the disease course and allow the use of lower doses of sulphonylurea to reduce the risk for dose-related adverse events. Combination therapy mainly used to treat patient having sulphonylurea failure. The mechanism of action of Saxagliptin hydrochloride and Glibenclamide is quite different. Saxagliptin hydrochloride inhibits the dpp-4 enzyme and promotes insulin synthesis and release. While Glibenclamide stimulation of insulin release from the B2 cells of the pancreas by blocking the ATP-sensitive k+ channels. The combination of both have decrease dose and improve the glycemic control. Combination of both the drugs were approved by us government and has been used in type-2 diabetes (diabetes mellitus). The main objective of this review article is to provide pharmacological information of combined therapy of saxagliptin hydrochloride and glibenclamide to researcher in development of combined dosage form of this.